Agenus Inc. - Common Stock (NQ:AGEN)

6.780 -0.310 (-4.37%)

Delayed Quote Updated: 12:17 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom ↗

April 12, 2024

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity.

Via Benzinga

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

April 12, 2024

From Agenus Inc.

Via Business Wire

Gold Moves Higher; Auddia Shares Surge ↗

April 08, 2024

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 0.1% on Monday. The Dow traded up 0.04% to 38,919.32 while the NASDAQ rose 0.11% to 16,266.07. The S&P 500...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 08, 2024

Via Benzinga

Earnings Preview For Agenus ↗

March 13, 2024

Via Benzinga

Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 08, 2024

Shares of Agenus Inc. (NASDAQ: AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. Agenus Inc. (NASDAQ: AGEN) declined 17% to $0.4181 on...

Via Benzinga

Crude Oil Moves Lower; Perion Network Shares Tumble ↗

April 08, 2024

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 50 points on Monday. The Dow traded up 0.21% to 38,983.94 while the NASDAQ rose 0.39% to 16,311.32. The S&P 500...

Via Benzinga

Topics Stocks

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

April 08, 2024

It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!

Via InvestorPlace

Down 75%. Is Agenus Stock a Buy on the Dip? ↗

April 08, 2024

Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.

Via The Motley Fool

RADCOM, Lotus Technology And 3 Stocks To Watch Heading Into Monday ↗

April 08, 2024

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Agenus Announces Reverse Stock Split of Common Stock

April 05, 2024

From Agenus Inc.

Via Business Wire

2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now? ↗

April 03, 2024

These stocks could rocket higher, but they also present significant risks.

Via The Motley Fool

3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million ↗

March 24, 2024

If you want the chance at possible absurd returns, then consider gambling on these stocks to turn $1,000 into $1 million.

Via InvestorPlace

Agenus (AGEN) Q4 2023 Earnings Call Transcript ↗

March 14, 2024

AGEN earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Agenus Reports Fourth Quarter and Full Year 2023 Results

March 14, 2024

From Agenus Inc.

Via Business Wire

Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

March 06, 2024

From Agenus Inc.

Via Business Wire

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 05, 2024

From Agenus Inc.

Via Business Wire

Earnings Scheduled For March 14, 2024 ↗

March 14, 2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

Via Benzinga

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

February 29, 2024

From Agenus Inc.

Via Business Wire

Agenus to Participate in Leerink Partners Global Biopharma Conference

February 26, 2024

From Agenus Inc.

Via Business Wire

Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today ↗

February 15, 2024

The company hopes to engineer a 1-for-20 reverse stock split.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 15, 2024

Via Benzinga

7 Analyst-Backed Stocks With Promising 10-Bagger Potential ↗

February 01, 2024

Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot.

Via InvestorPlace

Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 31, 2024

From Agenus Inc.

Via Business Wire

3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024 ↗

January 26, 2024

There are several potential biotech breakthroughs likely to occur in 2024, and these three biotech stocks could see substantial gains

Via InvestorPlace

Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population

January 22, 2024

From Agenus Inc.

Via Business Wire

Why LQR House Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket ↗

January 16, 2024

Shares of LQR House Inc. (NASDAQ: LQR) rose sharply in pre-market trading. Borg's investor group has acquired a 20% stake in LQR House. LQR House shares jumped 16.1% to $4.25 in pre-market trading Here...

Via Benzinga

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 05, 2024

From Agenus Inc.

Via Business Wire

Agenus to Participate in B. Riley Healthcare Conference

January 04, 2024

From Agenus Inc.

Via Business Wire

2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street ↗

December 24, 2023

These two biotech stocks could be poised for a trend reversal.

Via The Motley Fool

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.